Sunshine Biopharma, Inc.
SBFM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.02 | 0.08 |
| FCF Yield | 0.00% | -563.33% | -37.30% | -49.70% |
| EV / EBITDA | 0.00 | 4.75 | 1.75 | 0.45 |
| Quality | ||||
| ROIC | 0.00% | -6.90% | -5.30% | -7.86% |
| Gross Margin | 0.00% | 36.37% | 30.67% | 32.24% |
| Cash Conversion Ratio | 0.72 | 1.45 | 1.58 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.75% | 58.40% | 100.21% | 306.44% |
| Free Cash Flow Growth | 0.00% | 5.31% | 49.93% | -104.83% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 4.92 | 6.22 | 3.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -238.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.46 | 0.52 | 0.58 |
| Cash Conversion Cycle | 0.00 | 157.89 | 134.48 | 115.67 |